Reviewing Fate Therapeutics Inc. (FATE)’s and Proteostasis Therapeutics Inc. (NASDAQ:PTI)’s results

Fate Therapeutics Inc. (NASDAQ:FATE) and Proteostasis Therapeutics Inc. (NASDAQ:PTI) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as risk, institutional ownership, analyst recommendations, profitability, dividends, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Fate Therapeutics Inc. 19 0.00 63.25M -1.31 0.00
Proteostasis Therapeutics Inc. 3 0.00 40.00M -1.29 0.00

Table 1 shows the gross revenue, earnings per share (EPS) and valuation for Fate Therapeutics Inc. and Proteostasis Therapeutics Inc.


Table 2 shows Fate Therapeutics Inc. and Proteostasis Therapeutics Inc.’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
Fate Therapeutics Inc. 330,287,206.27% -48.9% -35.3%
Proteostasis Therapeutics Inc. 1,571,894,525.88% -69.9% -55.9%

Risk & Volatility

A 1.93 beta means Fate Therapeutics Inc.’s volatility is 93.00% more than S&P 500’s volatility. Proteostasis Therapeutics Inc. has a 0.11 beta and it is 89.00% less volatile than S&P 500.


Fate Therapeutics Inc.’s Current Ratio is 7.5 while its Quick Ratio is 7.5. On the competitive side is, Proteostasis Therapeutics Inc. which has a 6.9 Current Ratio and a 6.9 Quick Ratio. Fate Therapeutics Inc. is better positioned to pay off short and long-term obligations compared to Proteostasis Therapeutics Inc.

Analyst Ratings

Fate Therapeutics Inc. and Proteostasis Therapeutics Inc. Recommendations and Ratings are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Fate Therapeutics Inc. 0 0 7 3.00
Proteostasis Therapeutics Inc. 0 0 0 0.00

Fate Therapeutics Inc.’s upside potential is 8.54% at a $26.57 consensus target price.

Institutional & Insider Ownership

The shares of both Fate Therapeutics Inc. and Proteostasis Therapeutics Inc. are owned by institutional investors at 98.8% and 42.8% respectively. Fate Therapeutics Inc.’s share owned by insiders are 0.8%. Comparatively, 17.52% are Proteostasis Therapeutics Inc.’s share owned by insiders.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Fate Therapeutics Inc. -12.48% 2.09% -22.24% -17.55% -13.15% 6.55%
Proteostasis Therapeutics Inc. 45.49% 306.6% 333.46% 251.49% -28.71% 9.57%

For the past year Fate Therapeutics Inc. has weaker performance than Proteostasis Therapeutics Inc.


Fate Therapeutics Inc. beats on 6 of the 10 factors Proteostasis Therapeutics Inc.

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its immuno-oncology product candidates include FATE-NK100, a natural killer (NK) cell cancer immunotherapy that consists of adaptive memory NK cells; engineered hnCD16 induced pluripotent stem cells (iPSC)-derived natural killer cell therapy candidates for hematologic/solid tumors; and engineered chimeric antigen receptor iPSC-derived T cell therapy product candidates for hematologic/solid tumors. The companyÂ’s immuno-regulation product candidates comprise ProTmune, an investigational programmed cellular immunotherapy for use as a next-generation allogeneic hematopoietic cell transplantation cell graft; and ToleraCyte for the treatment of autoimmune and inflammatory diseases; engineered iPSC-derived CD34+ cell therapy for immune disorders. Fate Therapeutics, Inc. has a research collaboration and license agreement with Memorial Sloan Kettering Cancer Center to develop off-the-shelf T-cell immunotherapies; and strategic research collaboration and license agreement with Juno Therapeutics, Inc. to identify small molecule modulators that enhance the function of T cells. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.

Proteostasis Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics that treat diseases caused by dysfunctional protein processing, such as cystic fibrosis. Its lead product candidate is PTI-428, an orally bioavailable cystic fibrosis transmembrane conductance regulator modulator belonging to the amplifier class that is in Phase-I studies. The company is also developing PTI-801, a corrector molecule; PTI-808, a potentiator molecule; and unfolded protein response (UPR) modulators that are in preclinical development. It has collaboration with Astellas Pharma, Inc. to research and identify therapies targeting the Unfolded Protein Response (UPR) pathway. The company was formerly known as Proteoguard, Inc. and changed its name to Proteostasis Therapeutics, Inc. in September 2007. Proteostasis Therapeutics, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.